Disclosure Of First-Time Adoption [Text Block]

Egetis Therapeutics - Filing #678414

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Disclosure of first-time adoption [text block]
Disclosure of comparative information prepared under previous GAAP [text block]
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity
5,456,000,000 SEK
1 266,5 SEK
167,000,000 SEK
154,000,000 SEK
1 780,0 SEK
5,062,000,000 SEK
61,000,000 SEK
9,396,000,000 SEK
113,000,000 SEK
1 428,4 SEK
7,458,000,000 SEK
13,000,000 SEK
1 262,8 SEK
5,270,000,000 SEK
87,000,000 SEK
Comprehensive income
3,270,000,000 SEK
- SEK
3,270,000,000 SEK
- SEK
- SEK
- SEK
- SEK
1,938,000,000 SEK
1,938,000,000 SEK
- SEK
Profit (loss)
3,269,000,000 SEK
1,938,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.